HIPRA

HIPRA

Avda. la Selva. 135, 17170 Amer (Girona), España

Phone: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

HIPRA receives positive CHMP opinion from the European Medicines Agency for its COVID-19 vaccine adapted to XFG.1.1 variant

The biotechnology pharmaceutical company has adapted its COVID-19 vaccine in line with EMA recommendations for the 2026/2027 vaccination campaign

Girona, July 24, 2026 – HIPRA has received a positive opinion from the European Medicines Agency's Committee for Medicinal Product for Human Use (CHMP) for its recombinant protein COVID-19 vaccine, BIMERVAX®, adapted to the XFG.1.1 variant.

Once the European Commission grants the corresponding authorization, the adapted vaccine will be available for active immunization **to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older**[1]**.** This marks the third adaptation of HIPRA's COVID-19 vaccine matching variant recommendations.

The updated vaccine has been developed following the recommendation issued by the European Medicines Agency Emergency Task Force (EMA-ETF), which **identified the XFG variant as the preferred target for the 2026/2027 vaccination campaign**. The recommendation was based on the epidemiological situation and available evidence supporting broader protection against circulating JN.1-lineage variants[2].

Platform reinforcement and new presentations

As with previous adaptations, the vaccine has been developed using **HIPRA's recombinant protein platform**, allowing the antigen to be updated in response to the evolution of SARS-CoV-2 while maintaining the same squalene-based adjuvant, manufacturing technology and quality standards.

The updated vaccine will be available in **two ready-to-use presentations**: the existing **single-dose vial** and, for the first time, a **pre-filled syringe** (PFS). Both presentations are designed to **facilitate administration by healthcare professionals**, while the addition of the PFS provides an alternative presentation for routine clinical practice.

HIPRA

Avda. la Selva. 135, 17170 Amer (Girona), España

Phone: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

A new milestone to HIPRA's growth

This achievement further reflects HIPRA's capability to develop, adapt, manufacture and supply innovative vaccines. As **COVID-19 continues to circulate**, this new adaptation will add another option to **COVID-19 vaccination campaigns**, reinforcing the role of recombinant protein vaccines in the endemic phase of the disease.

Carles Fàbrega, Managing Director of HIPRA's Human Health division, said: "This is another important step in our commitment to make HIPRA a trusted partner to bring vaccines for people across Europe and worldwide. Receiving a positive CHMP opinion for our XFG.1.1 adapted vaccine is a milestone that reflects dedication, ability and teamwork".

BIMERVAX® has been developed by HIPRA and is manufactured at HIPRA's facilities in the province of Girona (Spain), where key stages of the vaccine's life cycle are integrated, including research and development, industrial-scale manufacturing, quality control, regulatory activities and final batch release.

These integrated capabilities reinforce HIPRA's contribution to Europe's strategic autonomy in health and its preparedness to respond to future public health emergencies.

About HIPRA

HIPRA is a biopharmaceutical company focused on prevention in animal and human health (**One Health**), with a broad portfolio of highly innovative vaccines and an advanced diagnostic service. Through its motto, **"Building immunity for a healthier world,"** HIPRA reaffirms its commitment to providing solutions that improve global health.

The company has a strong international presence, with **40 subsidiaries**, **3 R&D centers**, and **6 manufacturing sites** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network reaches nearly **100 additional countries**, covering all five continents.

Research and development are at the core of HIPRA's expertise. The company invests approximately **15% of its annual turnover** in R&D activities and infrastructure, focused on applying the latest scientific advances to develop innovative, high-quality vaccines.

HIPRA has a diversified vaccine portfolio based on multiple technological platforms. Its R&D teams work with a wide range of technologies and biological modalities.

HIPRA

Avda. la Selva. 135, 17170 Amer (Girona), España

Phone: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

To complement its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Press contacts

Irene Calle – icalle@harmon.es – M. 609 873 052

José María Nieto – jnieto@harmon.es – M. 689 186 062

References

1. European Medicines Agency (EMA). Bimervax: EPAR – Product Information [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/bimervax-epar-product-information_en.pdf

2. European Medicines Agency (EMA). ETF recommends updating COVID-19 vaccines to target XFG variant [Internet]. Amsterdam: European Medicines Agency; 2026 May 29 [cited 2026 Jul 6]. Available from: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-xfg-variant